An Essential Parameters of Captopril Include Objectives, Mechanism of Action, Pharmaco Kinetics, Administration, Adverse Effects, Drug-Drug Interaction, Contra Indications, Toxicity and Health Care Team Outcomes

Q: What is the clinical evidence from this study?

Study design: Review. Population: Adults with hypertension, heart failure, post-myocardial infarction with left ventricular dysfunction, or diabetic nephropathy (n=11000). Intervention: Captopril vs. Conventional therapy such as diuretics, beta-blockers; placebo; other ACE inhibitors (e.g., enalapril, lisinopril). Primary outcome: Cardiovascular morbidity and mortality, blood pressure reduction, left ventricular function improvement, proteinuria reduction in nephropathy (19% reduction in all-cause mortality post-MI (SAVE trial)).

Srinivas G.; Ramanjaneyulu D.V.; Satyanarayana Murthy S.; Muralinath E.; Guruprasad M.; Hari Kiran M.; Shaik Mahabooob Basha; Kundara Giridhar Reddy; Kasireddy Gauthami; Mopoori Kalyan; Sai Charan B; Sainath Reddy T.; Ramesh U.; Rahul P.; K. V. Rajitha

doi:10.5281/zenodo.18692935

February 19, 2026Open Access

An Essential Parameters of Captopril Include Objectives, Mechanism of Action, Pharmaco Kinetics, Administration, Adverse Effects, Drug-Drug Interaction, Contra Indications, Toxicity and Health Care Team Outcomes

View Full Paper

Ask AI

Bookmark

Share

Key result

Captopril cuts all-cause mortality ~19% in post-MI patients with LV dysfunction.

19% reduction in all-cause mortality post-MI (SAVE trial)
n=11,000

Why the study?

Understanding captopril's mechanism of action, dosage considerations, adverse event profile, and toxicities is essential for equipping interprofessional team members to safely administer it in clinical practice.

Key Points

To summarize the pharmacological mechanisms, clinical pharmacokinetics, therapeutic indications, and safety profile of captopril across cardiovascular and renal indications.
Synthesized findings from clinical investigations, including the SAVE trial and the ISIS-4 trial (enrolling more than 58,000 patients) evaluating captopril post-myocardial infarction.
Assessed pharmacological characteristics, adverse event reports, and dosage regimens typically ranging between 37.5 and 150 mg/day.
In ISIS-4, early initiation of captopril within 24 hours post-myocardial infarction reduced mortality at 5 weeks, while the SAVE study demonstrated relative mortality reduction in patients with left ventricular dysfunction.
Common adverse events include skin complaints in ~19% and taste disturbances in ~17% of patients with hypertension and renal or cardiac failure, whereas proteinuria occurred in ~0.7%, particularly at doses exceeding 150 mg/day.
Pharmacokinetic data indicate peak plasma concentration within approximately 1 hour, clearance of 0.7 L/h/kg, and an elimination half-life of roughly two hours, requiring administration one hour before meals and two to three daily doses.

Structured PICO

P

Population

Adults with hypertension, heart failure, post-myocardial infarction left ventricular dysfunction, or diabetic nephropathy.

I

Intervention

Captopril (oral, typically 25-150 mg/day in divided doses)

Main Result

Effect estimate: 19% reduction in all-cause mortality post-MI (SAVE trial)

Limitations

Major randomized trials comparing captopril to newer ACE inhibitors or newer antihypertensives are limited and mostly older studies
Short half-life requiring multiple daily doses may limit adherence
Higher incidence of rash and taste disturbances compared to second-generation ACE inhibitors
Safety and dosage in specific populations such as elderly, pregnant women, and sub-Saharan African populations are understudied
Relatively few recent major randomized trials directly compare captopril to more recent ACE inhibitors or newer groups of antihypertensive medications
Adherence can occasionally be limited by side effect burden and tolerability (particularly taste disturbances and skin responses)
The risk of adverse events is still significantly influenced by renal impairment, requiring further clarification on specific dosage recommendations

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Captopril is an effective, short-acting ACE inhibitor for managing hypertension, heart failure, post-MI LV dysfunction, and diabetic nephropathy, though it has been largely replaced by longer-acting agents in many clinical settings.

Abstract

Captopril is an FDA-approved medication that plays an important regarding management of hypertension, left ventricular dysfunction post-myocardial infarction, and diabetic nephropathy. It is a key component in the therapy of these cardiovascular disorders since it mainly works by blocking the renin-angiotensin-aldosterone system (RAAS). By preventing the conversion of angiotensin I to angiotensin II, captopril effectively reduces the pathophysiological cascades that lead to hypertension and heart failure. This activity explains regarding captopril's mechanism of action, dosage considerations, pharmacodynamics, and monitoring strategies. Besides. captopril's off-label uses in acute hypertensive crises, and the Raynaud phenomenon will be discussed, equipping clinicians and inter professional team members along with essential knowledge to administer captopril. Understanding its adverse event profile and potential toxicities is essential for the safe and effective incorporation of captopril into clinical practice.

Cite This Study

G. et al. (2026) conducted a review in Adults with hypertension, heart failure, post-myocardial infarction with left ventricular dysfunction, or diabetic nephropathy (n=11,000). Captopril vs. Conventional therapy such as diuretics, beta-blockers; placebo; other ACE inhibitors (e.g., enalapril, lisinopril) was evaluated on Cardiovascular morbidity and mortality, blood pressure reduction, left ventricular function improvement, proteinuria reduction in nephropathy (19% reduction in all-cause mortality post-MI (SAVE trial)).

synapsesocial.com/papers/69994cd2873532290d021988 https://doi.org/10.5281/zenodo.18692935

Topics

Hypertension management

View Full Paper

Ask AI

Bookmark

Share

An Essential Parameters of Captopril Include Objectives, Mechanism of Action, Pharmaco Kinetics, Administration, Adverse Effects, Drug-Drug Interaction, Contra Indications, Toxicity and Health Care Team Outcomes

Key Points

Structured PICO

Main Result

Limitations

Discussion

Implication

Abstract

Cite This Study

Topics

An Essential Parameters of Captopril Include Objectives, Mechanism of Action, Pharmaco Kinetics, Administration, Adverse Effects, Drug-Drug Interaction, Contra Indications, Toxicity and Health Care Team Outcomes

Key Points

Structured PICO

Main Result

Limitations

Discussion

Implication

Abstract

Cite This Study

Keep reading

More related papers

More on Hypertension management

Topics

Keep reading

More related papers

More on Hypertension management